RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Tritiation of the cannabinoid receptor antagonist SR144528 involving lithium aluminum tritide reduction; assessment of the kinetic isotope effect by H-3-NMR
Seltzman, H., Foster, MC., Wyrick, C., Burgess, J., & Carroll, F. (2005). Tritiation of the cannabinoid receptor antagonist SR144528 involving lithium aluminum tritide reduction; assessment of the kinetic isotope effect by H-3-NMR. Journal of Labelled Compounds and Radiopharmaceuticals, 48(8), 589-596. https://doi.org/10.1002/jlcr.952
The cannabinoid receptor antagonist SR144528 was synthesized by an approach that enabled the incorporation of high specific activity tritium label while circumventing the lability of the target compound to catalytic hydrogenation. Lithium aluminum tritide of less than maximum specific activity was employed to introduce tritium, resulting in an H/T incorporation indicative of no kinetic isotope effect for the hydride/tritide reduction of a methyl benzoate. Copyright (c) 2005 John Wiley & Sons, Ltd